MISSOURI CIRCUIT COURT TWENTY-FIRST JUDICIAL CIRCUIT ST. LOUIS COUNTY

BARBARA ALLEGREZZA, HELEN ANDERSON, MARCIA ARMSTRONG, WESLEY ATER, HARRY BAILEY, DORLINDA BEATTY, JOHN BELL, FRANK BELLCOUR, ROBERT BIRDSALL, FAITH BROSSEAU, JOSEPH BUCCI, AMANDA BUCKLEY, JONATHAN CAISSY, WILLIAM CESAROTTI, LESLIE COOPER, RICKY COSTNER, LILA CRABTREE, MILDRED CROSS, COLLIN DANNER, JOHN DAVIS, CHRISTOPHER DZIEPAK, BONNIE ELKINS, DEBORAH ENGLISH, KATIE FINAMORE,	Cause No. Division JURY TRIAL DEMANDED
SCOTTY FORD, PIM FOWLER, TIMMY FRANKLIN, JOSEPH GANGE, CAROLINE GARDNER, LEONEL GARZA, ROBERT GOAD, WANDA GREENE, RONALD GUTOWSKI, HERBERT HASEMANN, CHRIS HELMS, ROSETTA HEYDT, KATHLEEN HICKS, DIANA HILLIARD, VANNAH HOWARD, TERRANCE HYLAND, JOSEPHUS JACKSON, WANDA JACKSON,	

BARRY JENSEN, JOYCE JONES, DREW KERSTEN, **DEBORAH KRUEGER, BONNIE KRUK**, DANIEL KUEFFER, MARV LANCASTER, **DEBRA LEE,** MARTHA LITTMAN, **ROBERT LOOPE,** DAVID LOVE, **DEBRA LOVE**, **DAVID MARTIN,** MARK MCCOSTLIN, **TERESA MICHAELIS,** LATASHA MILLER, **MICHAEL MORAN, DARREL NARVESON, RENEE NASH**, **KADEEM NUNES, EDITH PAGE-BRADSHAW**, JUDITH PARANUK, JOY PAULZINE, **ROBERT POLLACK, DONALD PRESLEY, GUY PROCTOR**, **GUY RABICH**, JOHN ROBERTS, JANIE ROBLES, WILLIAM RODDY, JOAN SCHROEDER, **DUKES SHERROD**, **CODY SMITH**, NORM SPARROW, **BRENDA STANLEY,** KARI STEELE, JOHN SUMPTER, TIMOTHY TAULBEE, **EDITH THOMAS**, JOSEPH TROUT, NANCY VAN LOON, JEFFREY VAUGHN, **CHERI WAGNER, DERECK WALTZ,** KATHLEEN WATSON, THOMAS WILLIAMSON,

BRIAN WOLLE, and ELRAY YOUNG

Plaintiffs,

v.

MONSANTO COMPANY, Serve: Registered Agent CSC of St. Louis County, Inc. 130 South Bemiston Avenue Suite 700 Clayton, MO 63105

Defendant.

PETITION

COMES NOW Plaintiffs Barbara Allegrezza, Helen Anderson, Marcia Armstrong, Wesley Ater, Harry Bailey, Dorlinda Beatty, John Bell, Frank Bellcour, Robert Birdsall, Faith Brosseau, Joseph Bucci, Amanda Buckley, Jonathan Caissy, William Cesarotti, Leslie Cooper, Ricky Costner, Lila Crabtree, Mildred Cross, Collin Danner, John Davis, Christopher Dziepak, Bonnie Elkins, Deborah English, Katie Finamore, Scotty Ford, Pim Fowler, Timmy Franklin, Joseph Gange, Caroline Gardner, Leonel Garza, Robert Goad, Wanda Greene, Ronald Gutowski, Herbert Hasemann, Chris Helms, Rosetta Heydt, Kathleen Hicks, Diana Hilliard, Vannah Howard, Terrance Hyland, Josephus Jackson, Wanda Jackson, Barry Jensen, Joyce Jones, Drew Kersten, Deborah Krueger, Bonnie Kruk, Daniel Kueffer, Marv Lancaster, Debra Lee, Martha Littman, Robert Loope, David Love, Debra Love, David Martin, Mark McCostlin, Teresa Michaelis, Latasha Miller, Michael Moran, Darrel Narveson, Renee Nash, Kadeem Nunes, Edith Page-Bradshaw, Judith Paranuk, Joy Paulzine, Robert Pollack, Donald Presley, Guy Proctor, Guy Rabich, John Roberts, Janie Robles, William Roddy, Joan Schroeder, Dukes Sherrod, Cody Smith, Norm Sparrow, Brenda Stanley, Kari Steele, John Sumpter, Timothy Taulbee, Edith Thomas, Joseph Trout, Nancy Van Loon, Jeffrey Vaughn, Cheri Wagner, Dereck Waltz, Kathleen Watson, Thomas Williamson, Brian Wolle, and ElRay Young, and hereby bring this action against Defendant Monsanto Company, as follows:

INTRODUCTION

Plaintiffs bring this cause of action against Defendant for injuries and/or death sustained as a result of using Defendant's unreasonably dangerous and defective product, Roundup®. More specifically, Plaintiffs' claims involve Defendant's negligent, willful, and wrongful conduct in connection with the design, development, manufacture, testing, packaging, promoting, marketing, distribution, and/or sale of Roundup® and/or other Monsanto glyphosate-containing products ("Roundup" or "Roundup®"). As a direct and proximate result of their exposure to Roundup® and its reactive ingredient, glyphosate, Plaintiffs developed non-Hodgkin's Lymphoma.

THE PARTIES

Plaintiffs

1. Plaintiff Barbara Allegrezza is a resident of Tower, Minnesota. Plaintiff Barbara Allegrezza used Roundup in Minnesota for personal purposes between approximately 1990 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Barbara Allegrezza used Roundup as directed at all relevant times.

2. Plaintiff Helen Anderson is a resident of Baltimore, Maryland. Plaintiff Helen Anderson used Roundup, upon information and belief, in Maryland for personal purposes between approximately 1988 and 1993 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Helen Anderson used Roundup as directed at all relevant times.

3. Plaintiff Marcia Armstrong is a resident of Newton, New Jersey. Plaintiff Marcia Armstrong used Roundup, upon information and belief, in New Jersey for personal purposes

between approximately 2007 and 2017 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Marcia Armstrong used Roundup as directed at all relevant times.

4. Plaintiff Wesley Ater is a resident of Arlington, Texas. Plaintiff Wesley Ater used Roundup in Texas for personal purposes between approximately 1980 and 2000 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Wesley Ater used Roundup as directed at all relevant times.

5. Plaintiff Harry Bailey is a resident of Rochester, New York. Plaintiff Harry Bailey used Roundup in New York for personal purposes between approximately 1982 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Harry Bailey used Roundup as directed at all relevant times.

6. Plaintiff Dorlinda Beatty is a resident of Fremont, Nebraska. Plaintiff Dorlinda Beatty used Roundup in Nebraska for personal purposes between approximately 1985 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Dorlinda Beatty used Roundup as directed at all relevant times.

7. Plaintiff John Bell is a resident of Avoca, Michigan. Plaintiff John Bell used Roundup in Michigan for personal purposes between approximately 1986 and 2016 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff John Bell used Roundup as directed at all relevant times.

8. Plaintiff Frank Bellcour is a resident of Eden Valley, Minnesota. Plaintiff Frank Bellcour used Roundup in Minnesota for personal purposes between approximately 2009 and 2017 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Frank Bellcour used Roundup as directed at all relevant times.

9. Plaintiff Robert Birdsall is a resident of Barnegat Light, New Jersey. Plaintiff

Robert Birdsall used Roundup, upon information and belief, in New Jersey for personal purposes between approximately 1974 and 1990 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Robert Birdsall used Roundup as directed at all relevant times.

10. Plaintiff Faith Brosseau is a resident of Gardner, Massachusetts. Plaintiff Faith Brosseau used Roundup in Massachusetts for purposes between approximately 2003 and 2010 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Faith Brosseau used Roundup as directed at all relevant times.

11. Plaintiff Joseph Bucci is a resident of Norristown, Pennsylvania. Plaintiff Joseph Bucci used Roundup in Pennsylvania for personal purposes between approximately 2000 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Joseph Bucci used Roundup as directed at all relevant times.

12. Plaintiff Amanda Buckley is a resident of Tulsa, Oklahoma. Plaintiff Amanda Buckley used Roundup in Oklahoma for personal purposes between approximately 2003 and 2015 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Amanda Buckley used Roundup as directed at all relevant times.

13. Plaintiff Jonathan Caissy is a resident of Fairfax, Vermont. Plaintiff Jonathan Caissy used Roundup in Vermont for personal purposes between approximately 1982 and 1999 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Jonathan Caissy used Roundup as directed at all relevant times.

14. Plaintiff William Cesarotti is a resident of Shalimar, Florida. Plaintiff William Cesarotti used Roundup in Florida for personal purposes between approximately 1993 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff William Cesarotti used Roundup as directed at all relevant times.

15. Plaintiff Leslie Cooper is a resident of Lincoln Park, Michigan. Plaintiff Leslie Cooper used Roundup in Michigan for personal purposes between approximately 2015 and 2017 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Leslie Cooper used Roundup as directed at all relevant times.

16. Plaintiff Ricky Costner is a resident of Buffalo, New York. Plaintiff Ricky Costner used Roundup in New York for work-related purposes between approximately 2008 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Ricky Costner used Roundup as directed at all relevant times.

17. Plaintiff Lila Crabtree is a resident of Manchester, Tennessee. Plaintiff Lila Crabtree used Roundup in Tennessee for personal purposes between approximately 1982 and 2016 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Lila Crabtree used Roundup as directed at all relevant times.

18. Plaintiff Mildred Cross is a resident of Chicago, Illinois. Plaintiff Mildred Cross used Roundup in Illinois for personal purposes between approximately 1976 and 1986 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Mildred Cross used Roundup as directed at all relevant times.

19. Plaintiff Collin Danner is a resident of Litchfield, Minnesota. Plaintiff Collin Danner used Roundup in Minnesota for personal purposes between approximately 2008 and 2014 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Collin Danner used Roundup as directed at all relevant times.

20. Plaintiff John Davis is a resident of Coushatta, Louisiana. Plaintiff John Davis used Roundup in Louisiana for personal and work-related purposes between approximately 1974 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff John Davis

used Roundup as directed at all relevant times.

21. Plaintiff Christopher Dziepak is a resident of Mattawan, Michigan. Plaintiff Christopher Dziepak used Roundup in Michigan for personal purposes between approximately 2009 and 2017 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Christopher Dziepak used Roundup as directed at all relevant times.

22. Plaintiff Bonnie Elkins is a resident of Davenport, Iowa. Plaintiff Bonnie Elkins used Roundup in Iowa for personal purposes between approximately 1987 and 2011 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Bonnie Elkins used Roundup as directed at all relevant times.

23. Plaintiff Deborah English is a resident of Kingsport, Tennessee. Plaintiff Deborah English used Roundup in Tennessee for personal purposes between approximately 2015 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Deborah English used Roundup as directed at all relevant times.

24. Plaintiff Katie Finamore is a resident of Maysville, Kentucky. Plaintiff Katie Finamore used Roundup in Kentucky for work-related purposes between approximately 1997 and 2000 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Katie Finamore used Roundup as directed at all relevant times.

25. Plaintiff Scotty Ford is a resident of Columbia, Mississippi. Plaintiff Scotty Ford used Roundup in Mississippi for personal and work-related purposes between approximately 1998 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Scotty Ford used Roundup as directed at all relevant times.

26. Plaintiff Pim Fowler is a resident of Dandridge, Tennessee. Plaintiff Pim Fowler used Roundup in Tennessee for personal purposes between approximately 1980 and 2011 and

was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Pim Fowler used Roundup as directed at all relevant times.

27. Plaintiff Timmy Franklin is a resident of Elk Park, North Carolina. Plaintiff Timmy Franklin used Roundup in North Carolina for personal and work-related purposes between approximately 2007 and 2017 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Timmy Franklin used Roundup as directed at all relevant times.

28. Plaintiff Joseph Gange is a resident of Cranberry Township, Pennsylvania.
Plaintiff Joseph Gange used Roundup in Pennsylvania for personal purposes between
approximately 1993 and 2009 and was subsequently diagnosed with non-Hodgkin's Lymphoma.
Plaintiff Joseph Gange used Roundup as directed at all relevant times.

29. Plaintiff Caroline Gardner is a resident of Florence, Arizona. Plaintiff Caroline Gardner used Roundup in Arizona for work-related purposes between approximately 1995 and 2013 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Caroline Gardner used Roundup as directed at all relevant times.

30. Plaintiff Leonel Garza is a resident of Edinburg, Texas. Plaintiff Leonel Garza used Roundup in Texas for personal purposes between approximately 2009 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Leonel Garza used Roundup as directed at all relevant times.

31. Plaintiff Robert Goad is a resident of Wytheville, Virginia. Plaintiff Robert Goad used Roundup in Virginia for personal purposes between approximately 2012 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Robert Goad used Roundup as directed at all relevant times.

32. Plaintiff Wanda Greene is a resident of Sandusky, Ohio. Plaintiff Wanda Greene

used Roundup in Ohio for personal and work-related purposes between approximately 1989 and 2007 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Wanda Greene used Roundup as directed at all relevant times.

33. Plaintiff Ronald Gutowski is a resident of Abingdon, Maryland. Plaintiff Ronald Gutowski used Roundup in Maryland for personal purposes between approximately 2009 and 2017 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Ronald Gutowski used Roundup as directed at all relevant times.

34. Plaintiff Herbert Hasemann is a resident of Reno, Nevada. Plaintiff Herbert Hasemann used Roundup in Nevada for work-related purposes between approximately 1990 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Herbert Hasemann used Roundup as directed at all relevant times.

35. Plaintiff Chris Helms is a resident of Omaha, Nebraska. Plaintiff Chris Helms used Roundup in Nebraska for personal and work-related purposes between approximately 1987 and 1999 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Chris Helms used Roundup as directed at all relevant times.

36. Plaintiff Rosetta Heydt is a resident of Fleetwood, Pennsylvania. Plaintiff Rosetta Heydt used Roundup in Pennsylvania for personal purposes between approximately 1974 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Rosetta Heydt used Roundup as directed at all relevant times.

37. Plaintiff Kathleen Hicks is a resident of Powell, Wyoming. Plaintiff Kathleen Hicks used Roundup in Wyoming for personal purposes between approximately 1975 and 2014 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Kathleen Hicks used Roundup as directed at all relevant times.

38. Plaintiff Diana Hilliard is a resident of Scio, New York. Plaintiff Diana Hilliard used Roundup in New York for personal purposes between approximately 2009 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Diana Hilliard used Roundup as directed at all relevant times.

39. Plaintiff Vannah Howard is a resident of Carlisle, Ohio. Plaintiff Vannah Howard used Roundup in Ohio for personal purposes between approximately 2013 and 2016 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Vannah Howard used Roundup as directed at all relevant times.

40. Plaintiff Terrance Hyland is a resident of Conover, North Carolina. Plaintiff Terrance Hyland used Roundup, upon information and belief, in North Carolina for personal purposes between approximately 1974 and 2003 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Terrance Hyland used Roundup as directed at all relevant times.

41. Plaintiff Josephus Jackson is a resident of Uniontown, Alabama. Plaintiff Josephus Jackson used Roundup in Alabama for personal purposes between approximately 2011 and 2017 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Josephus Jackson used Roundup as directed at all relevant times.

42. Plaintiff Wanda Jackson is a resident of Durham, North Carolina. Plaintiff Wanda Jackson used Roundup in North Carolina for personal purposes between approximately 1998 and 2000 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Wanda Jackson used Roundup as directed at all relevant times.

43. Plaintiff Barry Jensen is a resident of Wausau, Wisconsin. Plaintiff Barry Jensen used Roundup in Wisconsin for personal purposes between approximately 2000 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Barry Jensen used

Roundup as directed at all relevant times.

44. Plaintiff Joyce Jones is a resident of Fountain Hills, Arizona. Plaintiff Joyce Jones used Roundup in Arizona for personal purposes between approximately 1990 and 2013 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Joyce Jones used Roundup as directed at all relevant times.

45. Plaintiff Drew Kersten is a resident of Rock Valley, Iowa. Plaintiff Drew Kersten used Roundup in Iowa for personal and work-related purposes between approximately 2010 and 2014 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Drew Kersten used Roundup as directed at all relevant times.

46. Plaintiff Deborah Krueger is a resident of Salisbury, North Carolina. Plaintiff Deborah Krueger used Roundup in North Carolina for personal purposes between approximately 1976 and 2009 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Deborah Krueger used Roundup as directed at all relevant times.

47. Plaintiff Bonnie Kruk is a resident of Reno, Nevada. Plaintiff Bonnie Kruk used Roundup in Nevada for personal purposes between approximately 2012 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Bonnie Kruk used Roundup as directed at all relevant times.

48. Plaintiff Daniel Kueffer is a resident of Sergeant Bluff, Iowa. Plaintiff Daniel Kueffer used Roundup in Iowa for personal purposes between approximately 2004 and 2016 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Daniel Kueffer used Roundup as directed at all relevant times.

49. Plaintiff Marv Lancaster is a resident of Tucson, Arizona. Plaintiff Marv Lancaster used Roundup in Arizona for personal purposes between approximately 1984 and

2000 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Marv Lancaster used Roundup as directed at all relevant times.

50. Plaintiff Debra Lee is a resident of Ashville, Alabama. Plaintiff Debra Lee used Roundup in Alabama for personal purposes between approximately 1990 and 1997 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Debra Lee used Roundup as directed at all relevant times.

51. Plaintiff Martha Littman is a resident of Greenville, South Carolina. Plaintiff Martha Littman used Roundup in South Carolina for personal purposes between approximately 1976 and 2016 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Martha Littman used Roundup as directed at all relevant times.

52. Plaintiff Robert Loope is a resident of North Bay, New York. Plaintiff Robert Loope used Roundup in New York for personal purposes between approximately 1995 and 2003 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Robert Loope used Roundup as directed at all relevant times.

53. Plaintiff David Love is a resident of Salt Lake City, Utah. Plaintiff David Love used Roundup in Utah for personal purposes between approximately 2002 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff David Love used Roundup as directed at all relevant times.

54. Plaintiff Debra Love is a resident of Las Vegas, Nevada. Plaintiff Debra Love used Roundup in Nevada for personal purposes between approximately 1992 and 2005 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Debra Love used Roundup as directed at all relevant times.

55. Plaintiff David Martin is a resident of Adelphi, Maryland. Plaintiff David Martin

used Roundup in Maryland for personal purposes between approximately 1989 and 2014 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff David Martin used Roundup as directed at all relevant times.

56. Plaintiff Mark McCostlin is a resident of Lenexa, Kansas. Plaintiff Mark McCostlin used Roundup in Kansas for work-related purposes between approximately 1988 and 2016 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Mark McCostlin used Roundup as directed at all relevant times.

57. Plaintiff Teresa Michaelis is a resident of Klamath Falls, Oregon. Plaintiff Teresa Michaelis used Roundup in Oregon for personal purposes between approximately 1978 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Teresa Michaelis used Roundup as directed at all relevant times.

58. Plaintiff Latasha Miller is a resident of Dothan, Alabama. Plaintiff Latasha Miller used Roundup in Alabama for personal purposes between approximately 1998 and 2008 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Latasha Miller used Roundup as directed at all relevant times.

59. Plaintiff Michael Moran is a resident of Harrison, New York. Plaintiff Michael Moran used Roundup in Alabama for personal purposes between approximately 1987 and 2012 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Michael Moran used Roundup as directed at all relevant times.

60. Plaintiff Darrel Narveson is a resident of Le Sueur, Minnesota. Plaintiff Darrel Narveson used Roundup in Minnesota for personal purposes between approximately 1974 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Darrel Narveson used Roundup as directed at all relevant times.

61. Plaintiff Renee Nash is a resident of Winston Salem, North Carolina. Plaintiff Renee Nash used Roundup in North Carolina for personal purposes between approximately 1978 and 2017 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Renee Nash used Roundup as directed at all relevant times.

62. Plaintiff Kadeem Nunes is a resident of Deerfield Beach, Florida. Plaintiff Kadeem Nunes used Roundup in Florida for work-related purposes between approximately 2015 and 2016 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Kadeem Nunes used Roundup as directed at all relevant times.

63. Plaintiff Edith Page-Bradshaw is a resident of Austin, Texas. Plaintiff Edith Page-Bradshaw used Roundup in Texas for personal purposes between approximately 1993 and 2013 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Edith Page-Bradshaw used Roundup as directed at all relevant times.

64. Plaintiff Judith Paranuk is a resident of Hampton, Virginia. Plaintiff Judith Paranuk used Roundup in Virginia for personal purposes between approximately 2004 and 2013 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Judith Paranuk used Roundup as directed at all relevant times.

65. Plaintiff Joy Paulzine is a resident of Dalbo, Minnesota. Plaintiff Joy Paulzine used Roundup in Minnesota for personal purposes between approximately 1985 and 1998 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Joy Paulzine used Roundup as directed at all relevant times.

66. Plaintiff Robert Pollack is a resident of Garner, North Carolina. Plaintiff Robert Pollack used Roundup in North Carolina for personal purposes between approximately 1979 and 2018 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Robert Pollack

used Roundup as directed at all relevant times.

67. Plaintiff Donald Presley is a resident of Terrell, Texas. Plaintiff Donald Presley used Roundup in Texas for personal purposes between approximately 1984 and 2001 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Donald Presley used Roundup as directed at all relevant times.

68. Plaintiff Guy Proctor is a resident of Cary, North Carolina. Plaintiff Guy Proctor used Roundup in North Carolina for personal purposes between approximately 2003 and 2004 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Guy Proctor used Roundup as directed at all relevant times.

69. Plaintiff Guy Rabich is a resident of Sarasota, Florida. Plaintiff Guy Rabich used Roundup in Florida for personal purposes between approximately 1993 and 2000 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Guy Rabich used Roundup as directed at all relevant times.

70. Plaintiff John Roberts is a resident of Woodstock, Virginia. Plaintiff John Roberts used Roundup in Virginia for personal and work-related purposes between approximately 1985 and 2001 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff John Roberts used Roundup as directed at all relevant times.

71. Plaintiff Janie Robles is a resident of Vernon, Texas. Plaintiff Janie Robles used Roundup in Texas for personal and work-related purposes between approximately 1996 and 2015 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Janie Robles used Roundup as directed at all relevant times.

72. Plaintiff William Roddy is a resident of Wichita, Kansas. Plaintiff William Roddy used Roundup in Kansas for personal purposes between approximately 1977 and 2019

and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff William Roddy used Roundup as directed at all relevant times.

73. Plaintiff Joan Schroeder is a resident of North Fort Myers, Florida. Plaintiff Joan Schroeder used Roundup in Florida for personal purposes between approximately 1980 and 2007 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Joan Schroeder used Roundup as directed at all relevant times.

74. Plaintiff Dukes Sherrod is a resident of Knoxville, Tennessee. Plaintiff Dukes Sherrod used Roundup in Tennessee for personal purposes between approximately 1980 and 2000 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Dukes Sherrod used Roundup as directed at all relevant times.

75. Plaintiff Cody Smith is a resident of Glendale, Arizona. Plaintiff Cody Smith used Roundup in Arizona for personal purposes between approximately 2004 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Cody Smith used Roundup as directed at all relevant times.

76. Plaintiff Norm Sparrow is a resident of Lehi, Utah. Plaintiff Norm Sparrow used Roundup in Utah for personal purposes between approximately 1980 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Norm Sparrow used Roundup as directed at all relevant times.

77. Plaintiff Brenda Stanley is a resident of Panama City Beach, Florida. Plaintiff Brenda Stanley used Roundup in Florida for personal purposes between approximately 2000 and 2011 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Brenda Stanley used Roundup as directed at all relevant times.

78. Plaintiff Kari Steele is a resident of Westland, Michigan. Plaintiff Kari Steele

used Roundup in Michigan for personal purposes between approximately 2002 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Kari Steele used Roundup as directed at all relevant times.

79. Plaintiff John Sumpter is a resident of Crofton, Maryland. Plaintiff John Sumpter used Roundup in Maryland for work-related purposes between approximately 1998 and 2004 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff John Sumpter used Roundup as directed at all relevant times.

80. Plaintiff Timothy Taulbee is a resident of Leslie, Michigan. Plaintiff Timothy Taulbee used Roundup in Michigan for personal purposes between approximately 2000 and 2004 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Timothy Taulbee used Roundup as directed at all relevant times.

81. Plaintiff Edith Thomas is a resident of Albany, New York. Plaintiff Edith Thomas used Roundup in New York for personal purposes between approximately 2000 and 2005 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Edith Thomas used Roundup as directed at all relevant times.

82. Plaintiff Joseph Trout is a resident of Lenoir City, Tennessee. Plaintiff Joseph Trout used Roundup in Tennessee for personal purposes between approximately 1978 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma Plaintiff Joseph Trout used Roundup as directed at all relevant times.

83. Plaintiff Nancy Van Loon is a resident of Evart, Michigan. Plaintiff Nancy Van Loon used Roundup in Michigan for personal purposes between approximately 2008 and 2014 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Nancy Van Loon used Roundup as directed at all relevant times.

84. Plaintiff Jeffrey Vaughn is a resident of Houston, Texas. Plaintiff Jeffrey Vaughn used Roundup in Texas for work-related purposes between approximately 1997 and 2011 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Jeffrey Vaughn used Roundup as directed at all relevant times.

85. Plaintiff Cheri Wagner is a resident of Covington, Ohio. Plaintiff Cheri Wagner used Roundup in Ohio for personal purposes between approximately 2001 and 2008 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Cheri Wagner used Roundup as directed at all relevant times.

86. Plaintiff Dereck Waltz is a resident of Brookville, Indiana. Plaintiff Dereck Waltz used Roundup in Indiana for personal purposes between approximately 2008 and 2011 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Dereck Waltz used Roundup as directed at all relevant times.

87. Plaintiff Kathleen Watson is a resident of Whitney, Texas. Plaintiff Kathleen Watson used Roundup in Texas for personal and work-related purposes between approximately 1990 and 1995 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Kathleen Watson used Roundup as directed at all relevant times.

88. Plaintiff Thomas Williamson is a resident of Conway, South Carolina. Plaintiff Thomas Williamson used Roundup in South Carolina for work-related purposes between approximately 1989 and 2005 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Thomas Williamson used Roundup as directed at all relevant times.

89. Plaintiff Brian Wolle is a resident of New Windsor, Maryland. Plaintiff Brian Wolle used Roundup in Maryland for work-related purposes between approximately 2006 and 2014 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff Brian Wolle

used Roundup as directed at all relevant times.

90. Plaintiff ElRay Young is a resident of Richfield, Utah. Plaintiff ElRay Young used Roundup in Utah for personal purposes between approximately 1979 and 2019 and was subsequently diagnosed with non-Hodgkin's Lymphoma. Plaintiff ElRay Young used Roundup as directed at all relevant times.

<u>Defendant</u>

91. Defendant Monsanto Company ("Monsanto") is a Delaware corporation with its headquarters and principal place of business in St. Louis, Missouri.

92. At all times relevant to this Petition, Monsanto was the entity that discovered the herbicidal properties of glyphosate and the manufacturer of Roundup®.

NATURE OF THE ACTION

93. In 1970, Defendant Monsanto Company discovered the herbicidal properties of glyphosate and began marketing it in products in 1974 under the brand name Roundup®. Roundup® is a non-selective herbicide used to kill weeds that commonly compete with the growing of crops. By 2001, glyphosate had become the most-used active ingredient in American agriculture with 85–90 millions of pounds used annually. That number grew to 185 million pounds by 2007. As of 2013, glyphosate was the world's most widely used herbicide.

94. Monsanto is a multinational agricultural biotechnology corporation based in St. Louis, Missouri. It is the world's leading producer of glyphosate. As of 2009, Monsanto was the world's leading producer of seeds, accounting for 27% of the world seed market. The majority of these seeds are of the Roundup Ready® brand. The stated advantage of Roundup Ready® crops is that they substantially improve a farmer's ability to control weeds, since glyphosate can be sprayed in the fields during the growing season without harming their crops. In 2010, an estimated

70% of corn and cotton, and 90% of soybean fields in the United States were Roundup Ready®.

95. Monsanto's glyphosate products are registered in 130 countries and approved for use on over 100 different crops. They are ubiquitous in the environment. Numerous studies confirm that glyphosate is found in rivers, streams, and groundwater in agricultural areas where Roundup® is used. It has been found in food, in the urine of agricultural workers, and even in the urine of urban dwellers who are not in direct contact with glyphosate.

96. On March 20, 2015, the International Agency for Research on Cancer ("IARC"), an agency of the World Health Organization ("WHO"), issued an evaluation of several herbicides, including glyphosate. That evaluation was based, in part, on studies of exposures to glyphosate in several countries around the world, and it traces the health implications from exposure to glyphosate since 2001.

97. On July 29, 2015, IARC issued the formal monograph relating to glyphosate. In that monograph, the IARC Working Group provides a thorough review of the numerous studies and data relating to glyphosate exposure in humans.

98. The IARC Working Group classified glyphosate as a Group 2A herbicide, which means that it is probably carcinogenic to humans. The IARC Working Group concluded that the cancers most associated with glyphosate exposure are non-Hodgkin lymphoma and other hematopoietic cancers, including lymphocytic lymphoma/chronic lymphocytic leukemia, B-cell lymphoma, and multiple myeloma.

99. The IARC evaluation is significant. It confirms that glyphosate is toxic to humans.

100. Nevertheless, Monsanto, since it began selling Roundup®, has represented it as safe to humans and the environment. Indeed, Monsanto has repeatedly proclaimed and continues to proclaim to the world, and particularly to United States consumers, that glyphosate-based

herbicides, including Roundup®, create no unreasonable risks to human health or to the environment.

JURISDICTION AND VENUE

101. At all times relevant hereto, Monsanto engaged in the business of researching, designing, formulating, compounding, testing, manufacturing, producing, processing, assembling, inspecting, distributing, labeling, and packaging and Monsanto engaged in marketing, promoting, and/or advertising Roundup® products in the State of Missouri and the County of St. Louis.

102. At all times relevant hereto, Monsanto was a Delaware corporation with its headquarters and principal place of business in St. Louis, Missouri, and therefore is a local, or forum, defendant for purposes of removal and diversity jurisdiction under 28 U.S.C. § 1441(b)(2).

103. Venue is proper in St. Louis County under RSMo. §508.010.5(1) because this is a tort case in which Plaintiffs were first injured outside of Missouri, and the registered agent for Defendant is located in St. Louis County.

104. The claims in this case present common questions of fact and law concerning, among other things, what information Monsanto possessed concerning the harmful effects of Roundup® and/or glyphosate, what information Monsanto disclosed to consumers about those harmful effects, and what information Monsanto was required by law to disclose about those effects. Plaintiffs herein are properly joined pursuant to the Missouri rule on permissive joinder, Missouri Rule of Civil Procedure 52.05(a). Plaintiffs' claims are logically related in that all Plaintiffs claim that Roundup® was defectively designed, manufactured and marketed by Monsanto and that Monsanto failed to provide appropriate warning and instructions regarding the dangers posed by Roundup® and/or glyphosate. All Plaintiffs suffered similar injuries and/or death as a result of using Roundup®. Monsanto's wrongful conduct, which resulted in Plaintiffs'

injuries and/or death, is common to all Plaintiffs and includes, but is not limited to, Monsanto's failure to conduct adequate safety and efficacy studies, Monsanto's submissions to the United States Environmental Protection Agency, Monsanto's marketing materials and literature promoting the safety of Roundup®, and the lack of adequate warnings provided to consumers. Monsanto's conduct in designing, developing, marketing, and distributing Roundup® relates to all Plaintiffs herein and makes up a common universe of facts underlying Plaintiffs' claims, such that Plaintiffs' claims against Monsanto arise from the same transaction or occurrence or the same series of transactions or occurrences.

FACTS

105. Glyphosate is a broad-spectrum, non-selective herbicide used in a wide variety of herbicidal products around the world.

106. Plants treated with glyphosate translocate the systemic herbicide to their roots, shoot regions and fruit, where it interferes with the plant's ability to form aromatic amino acids necessary for protein synthesis. Treated plants generally die within two to three days. Because plants absorb glyphosate, it cannot be completely removed by washing or peeling produce or by milling, baking, or brewing grains.

107. For nearly 40 years, farms across the world have used Roundup® without knowing of the dangers its use poses. That is because when Monsanto first introduced Roundup®, it touted glyphosate as a technological breakthrough: it could kill almost every weed without causing harm either to people or to the environment. Of course, history has shown that not to be true. According to the WHO, the main chemical ingredient of Roundup®—glyphosate—is a probable cause of cancer. Those most at risk are farm workers and other individuals with workplace exposure to Roundup®, such as workers in garden centers, nurseries, and landscapers. Agricultural workers

are, once again, victims of corporate greed. Monsanto assured the public that Roundup® was harmless. In order to prove this, Monsanto championed falsified data and attacked legitimate studies that revealed its dangers. Monsanto led a prolonged campaign of misinformation to convince government agencies, farmers, and the general population that Roundup® was safe.

The Discovery of Glyphosate and Development of Roundup®

108. The herbicidal properties of glyphosate were discovered in 1970 by Monsanto chemist John Franz. The first glyphosate-based herbicide was introduced to the market in the mid-1970s under the brand name Roundup®. From the outset, Monsanto marketed Roundup® as a "safe" general-purpose herbicide for widespread commercial and consumer use; Monsanto still markets Roundup® as safe today.

Registration of Herbicides under Federal Law

109. The manufacture, formulation and distribution of herbicides, such as Roundup®, are regulated under the Federal Insecticide, Fungicide, and Rodenticide Act ("FIFRA" or "Act"), 7 U.S.C. § 136 et seq. FIFRA requires that all pesticides be registered with the Environmental Protection Agency ("EPA" or "Agency") prior to their distribution, sale, or use, except as described by the Act. 7 U.S.C. § 136a(a).

110. Because pesticides are toxic to plants, animals, and humans, at least to some degree, the EPA requires as part of the registration process, among other things, a variety of tests to evaluate the potential for exposure to pesticides, toxicity to people and other potential non-target organisms, and other adverse effects on the environment. Registration by the EPA, however, is not an assurance or finding of safety. The determination the Agency must make in registering or reregistering a product is not that the product is "safe," but rather that use of the product in accordance with its label directions "will not generally cause unreasonable adverse effects on the environment." 7 U.S.C. § 136a(c)(5)(D).

111. FIFRA defines "unreasonable adverse effects on the environment" to mean "any unreasonable risk to man or the environment, taking into account the economic, social, and environmental costs and benefits of the use of any pesticide." 7 U.S.C. § 136(bb). FIFRA thus requires EPA to make a risk/benefit analysis in determining whether a registration should be granted or allowed to continue to be sold in commerce.

112. The EPA registered Roundup® for distribution, sale, and manufacture in the United States and, specifically, the State of Missouri.

113. FIFRA generally requires that the registrant, Monsanto in the case of Roundup®, conducts the health and safety testing of pesticide products. The EPA has protocols governing the conduct of tests required for registration and the laboratory practices that must be followed in conducting these tests. The data produced by the registrant must be submitted to the EPA for review and evaluation. The government is not required, nor is it able, however, to perform the product tests that are required of the manufacturer.

114. The evaluation of each pesticide product distributed, sold, or manufactured is completed at the time the product is initially registered. The data necessary for registration of a pesticide has changed over time. The EPA is now in the process of re-evaluating all pesticide products through a Congressionally-mandated process called "re-registration." 7 U.S.C. § 136a-1. In order to reevaluate these pesticides, the EPA is demanding the completion of additional tests and the submission of data for the EPA's review and evaluation.

115. In the case of glyphosate, and therefore Roundup®, the EPA had planned on releasing its preliminary risk assessment —in relation to the re-registration process—no later than July 2015. The EPA completed its review of glyphosate in early 2015, but it delayed releasing the

risk assessment pending further review in light of the WHO's health-related findings.

Scientific Fraud Underlying the Marketing and Sale of Glyphosate/Roundup

116. Based on early studies that glyphosate could cause cancer in laboratory animals, the EPA originally classified glyphosate as possibly carcinogenic to humans (Group C) in 1985. After pressure from Monsanto, including contrary studies it provided to the EPA, the EPA changed its classification to evidence of non-carcinogenicity in humans (Group E) in 1991. In so classifying glyphosate, however, the EPA made clear that the designation did not mean the chemical does not cause cancer: "It should be emphasized, however, that designation of an agent in Group E is based on the available evidence at the time of evaluation and should not be interpreted as a definitive conclusion that the agent will not be a carcinogen under any circumstances."

117. On two occasions, the EPA found that the laboratories hired by Monsanto to test the toxicity of its Roundup® products for registration purposes committed fraud.

118. In the first instance, Monsanto, in seeking initial registration of Roundup® by EPA, hired Industrial Bio-Test Laboratories ("IBT") to perform and evaluate pesticide toxicology studies relating to Roundup®. IBT performed about 30 tests on glyphosate and glyphosate-containing products, including nine of the 15 residue studies needed to register Roundup®.

119. In 1976, the United States Food and Drug Administration ("FDA") performed an inspection of Industrial Bio-Test Industries ("IBT") that revealed discrepancies between the raw data and the final report relating to the toxicological impacts of glyphosate. The EPA subsequently audited IBT; it too found the toxicology studies conducted for the Roundup® herbicide to be invalid. An EPA reviewer stated, after finding "routine falsification of data" at IBT, that it was "hard to believe the scientific integrity of the studies when they said they took specimens of the uterus from male rabbits."

120. Three top executives of IBT were convicted of fraud in 1983.

121. In the second incident of data falsification, Monsanto hired Craven Laboratories in 1991 to perform pesticide and herbicide studies, including for Roundup®. In that same year, the owner of Craven Laboratories and three of its employees were indicted, and later convicted, of fraudulent laboratory practices in the testing of pesticides and herbicides.

122. Despite the falsity of the tests that underlie its registration, within a few years of its launch, Monsanto was marketing Roundup® in 115 countries.

The Importance of Roundup® to Monsanto's Market Dominance Profits

123. The success of Roundup® was key to Monsanto's continued reputation and dominance in the marketplace. Largely due to the success of Roundup® sales, Monsanto's agriculture division was out-performing its chemicals division's operating income, and that gap increased yearly. But with its patent for glyphosate expiring in the United States in the year 2000, Monsanto needed a strategy to maintain its Roundup® market dominance and to ward off impending competition.

124. In response, Monsanto began the development and sale of genetically engineered Roundup Ready® seeds in 1996. Since Roundup Ready® crops are resistant to glyphosate; farmers can spray Roundup® onto their fields during the growing season without harming the crop. This allowed Monsanto to expand its market for Roundup® even further; by 2000, Monsanto's biotechnology seeds were planted on more than 80 million acres worldwide and nearly 70% of American soybeans were planted from Roundup Ready® seeds. It also secured Monsanto's dominant share of the glyphosate/Roundup® market through a marketing strategy that coupled proprietary Roundup Ready® seeds with continued sales of its Roundup® herbicide.

125. Through a three-pronged strategy of increased production, decreased prices, and by

coupling with Roundup Ready® seeds, Roundup® became Monsanto's most profitable product. In 2000, Roundup® accounted for almost \$2.8 billion in sales, outselling other herbicides by a margin of five to one, and accounting for close to half of Monsanto's revenue. Today, glyphosate remains one of the world's largest herbicides by sales volume.

Monsanto has known for decades that it falsely advertises the safety of Roundup®

126. In 1996, the New York Attorney General ("NYAG") filed a lawsuit against Monsanto based on its false and misleading advertising of Roundup ® products. Specifically, the lawsuit challenged Monsanto's general representations that its spray-on glyphosate-based herbicides, including Roundup®, were "safer than table salt" and "practically non-toxic" to mammals, birds, and fish. Among the representations the NYAG found deceptive and misleading about the human and environmental safety of Roundup® are the following:

- a) Remember that environmentally friendly Roundup herbicide is biodegradable. It won't build up in the soil so you can use Roundup with confidence along customers' driveways, sidewalks and fences.
- b) And remember that Roundup is biodegradable and won't build up in the soil. That will give you the environmental confidence you need to use Roundup everywhere you've got a weed, brush, edging or trimming problem.
- c) Roundup biodegrades into naturally occurring elements.
- d) Remember that versatile Roundup herbicide stays where you put it. That means there's no washing or leaching to harm customers' shrubs or other desirable vegetation.

- e) This non-residual herbicide will not wash or leach in the soil. It... stays where you apply it.
- f) You can apply Accord (another glyphosate-containing Monsanto herbicide) with "confidence because it will stay where you put it" it bonds tightly to soil particles, preventing leaching. Then, soon after application, soil microorganisms biodegrade Accord into natural products.
- g) Glyphosate is less toxic to rats than table salt following acute oral ingestion.
- h) Glyphosate's safety margin is much greater than required. It has over a 1,000-fold safety margin in food and over a 700-fold safety margin for workers who manufacture it or use it.
- You can feel good about using herbicides by Monsanto. They carry a toxicity category rating of 'practically non-toxic' as it pertains to mammals, birds and fish.
- j) "Roundup can be used where kids and pets will play and breaks down into natural material." This ad depicts a person with his head in the ground and a pet dog standing in an area which has been treated with Roundup.

127. On November 19, 1996, Monsanto entered into an Assurance of Discontinuance with NYAG, in which Monsanto agreed, among other things, "to cease and desist from publishing or broadcasting any advertisements [in New York] that represent, directly or by implication" that:

a) its glyphosate-containing pesticide products or any component

thereof are safe, non-toxic, harmless or free from risk. ***

- b) its glyphosate-containing pesticide products or any component thereof manufactured, formulated, distributed or sold by Monsanto are biodegradable ***
- c) its glyphosate-containing pesticide products or any component thereof stay where they are applied under all circumstances and will not move through the environment by any means. ***
- d) its glyphosate-containing pesticide products or any component thereof are "good" for the environment or are "known for their environmental characteristics." * * *
- e) glyphosate-containing pesticide products or any component thereof are safer or less toxic than common consumer products other than herbicides;
- f) its glyphosate-containing products or any component thereof might be classified as "practically non-toxic."

128. Monsanto did not alter its advertising in the same manner in any state other than New York, and on information and belief still has not done so today.

129. In 2009, France's highest court ruled that Monsanto had not told the truth about the safety of Roundup®. The French court affirmed an earlier judgement that Monsanto had falsely advertised its herbicide Roundup® as "biodegradable" and that it "left the soil clean."

Classifications and Assessments of Glyphosate

130. The IARC process for the classification of glyphosate followed the stringent procedures for the evaluation of a chemical agent. Over time, the IARC Monograph program has

reviewed 980 agents. Of those reviewed, it has determined 116 agents to be Group 1 (Known Human Carcinogens); 73 agents to be Group 2A (Probable Human Carcinogens); 287 agents to be Group 2B (Possible Human Carcinogens); 503 agents to be Group 3 (Not Classified); and one agent to be Probably Not Carcinogenic.

131. The established procedure for IARC Monograph evaluations is described in the IARC Programme's Preamble. Evaluations are performed by panels of international experts, selected on the basis of their expertise and the absence of actual or apparent conflicts of interest.

132. One year before the Monograph meeting, the meeting is announced and there is a call both for data and for experts. Eight months before the Monograph meeting, the Working Group membership is selected and the sections of the Monograph are developed by the Working Group members. One month prior to the Monograph meeting, the call for data is closed and the various draft sections are distributed among Working Group members for review and comment. Finally, at the Monograph meeting, the Working Group finalizes review of all literature, evaluates the evidence in each category, and completes the overall evaluation. Within two weeks after the Monograph meeting, the summary of the Working Group findings is published in Lancet Oncology, and within a year after the meeting, the final Monograph is finalized and published.

133. In assessing an agent, the IARC Working Group reviews the following information:

- a) human, experimental, and mechanistic data;
- b) all pertinent epidemiological studies and cancer bioassays; and
- c) representative mechanistic data. The studies must
 be publicly available and have sufficient detail for
 meaningful review, and reviewers cannot be

associated with the underlying study.

134. In March 2015, IARC reassessed glyphosate. The summary published in The Lancet Oncology reported that glyphosate is a Group 2A agent and probably carcinogenic in humans.

135. On July 29, 2015, IARC issued its Monograph for glyphosate, Monograph 112. For Volume 112, the volume that assessed glyphosate, a Working Group of 17 experts from 11 countries met at IARC from March 3–10, 2015, to assess the carcinogenicity of certain herbicides, including glyphosate. The March meeting culminated nearly a one-year review and preparation by the IARC Secretariat and the Working Group, including a comprehensive review of the latest available scientific evidence. According to published procedures, the Working Group considered "reports that have been published or accepted for publication in the openly available scientific literature" as well as "data from governmental reports that are publicly available."

136. The studies considered the following exposure groups: occupational exposure of farmers and tree nursery workers in the United States, forestry workers in Canada and Finland, and municipal weed-control workers in the United Kingdom; and para-occupational exposure in farming families.

137. Glyphosate was identified as the second-most used household herbicide in the United States for weed control between 2001 and 2007 and the most heavily used herbicide in the world in 2012.

138. Exposure pathways are identified as air (especially during spraying), water, and food. Community exposure to glyphosate is widespread and found in soil, air, surface water, and groundwater, as well as in food.

139. The assessment of the IARC Working Group identified several case control studies

of occupational exposure in the United States, Canada, and Sweden. These studies show a human health concern from agricultural and other work-related exposure to glyphosate.

140. The IARC Working Group found an increased risk between exposure to glyphosate and non-Hodgkin lymphoma ("NHL") and several subtypes of NHL, and the increased risk persisted after adjustment for other pesticides.

141. The IARC Working Group also found that glyphosate caused DNA and chromosomal damage in human cells. One study in community residents reported increases in blood markers of chromosomal damage (micronuclei) after glyphosate formulations were sprayed.

142. In male CD-1 mice, glyphosate induced a positive trend in the incidence of a rare tumor, renal tubule carcinoma. A second study reported a positive trend for haemangiosarcoma in male mice. Glyphosate increased pancreatic islet-cell adenoma in male rats in two studies. A glyphosate formulation promoted skin tumors in an initiation-promotion study in mice.

143. The IARC Working Group also noted that glyphosate has been detected in the urine of agricultural workers, indicating absorption. Soil microbes degrade glyphosate to aminomethylphosphoric acid (AMPA). Blood AMPA detection after exposure suggests intestinal microbial metabolism in humans.

144. The IARC Working Group further found that glyphosate and glyphosate formulations induced DNA and chromosomal damage in mammals, and in human and animal cells in utero.

145. The IARC Working Group also noted genotoxic, hormonal, and enzymatic effects in mammals exposed to glyphosate. Essentially, glyphosate inhibits the biosynthesis of aromatic amino acids, which leads to several metabolic disturbances, including the inhibition of protein and secondary product biosynthesis and general metabolic disruption. 146. The IARC Working Group also reviewed an Agricultural Health Study, consisting of a prospective cohort of 57,311 licensed pesticide applicators in Iowa and North Carolina. While this study differed from others in that it was based on a self-administered questionnaire, the results support an association between glyphosate exposure and Multiple Myeloma, Hairy Cell Leukemia (HCL), and Chronic Lymphocytic Leukemia (CLL), in addition to several other cancers.

Other Earlier Findings About Glyphosate's Dangers to Human Health

147. The EPA has a technical fact sheet, as part of its Drinking Water and Health, National Primary Drinking Water Regulations publication, relating to glyphosate. This technical fact sheet predates the IARC March 20, 2015, evaluation. The fact sheet describes the release patterns for glyphosate as follows:

Release Patterns

148. Glyphosate is released to the environment in its use as an herbicide for controlling woody and herbaceous weeds on forestry, right-of-way, cropped and non-cropped sites. These sites may be around water and in wetlands. It may also be released to the environment during its manufacture, formulation, transport, storage, disposal, and cleanup, and from spills. Since glyphosate is not a listed chemical in the Toxics Release Inventory, data on releases during its manufacture and handling are not available. Occupational workers and home gardeners may be exposed to glyphosate by inhalation and dermal contact during spraying, mixing, and cleanup. They may also be exposed by touching soil and plants to which glyphosate was applied. Occupational exposure may also occur during glyphosate's manufacture, transport storage, and disposal.

149. In 1995, the Northwest Coalition for Alternatives to Pesticides reported that in California, the state with the most comprehensive program for reporting of pesticide-caused

illness, glyphosate was the third most commonly-reported cause of pesticide illness among agricultural workers.

Recent Worldwide Bans on Roundup®/Glyphosate

150. Several countries around the world have instituted bans on the sale of Roundup® and other glyphosate-containing herbicides, both before and since IARC first announced its assessment for glyphosate in March 2015, and more countries undoubtedly will follow suit as the dangers of the use of Roundup® are more widely known. The Netherlands issued a ban on all glyphosate-based herbicides in April 2014, including Roundup®, which took effect by the end of 2015. In issuing the ban, the Dutch Parliament member who introduced the successful legislation stated: "Agricultural pesticides in user-friendly packaging are sold in abundance to private persons. In garden centers, Roundup® is promoted as harmless, but unsuspecting customers have no idea what the risks of this product are. Especially children are sensitive to toxic substances and should therefore not be exposed to it."

151. The Brazilian Public Prosecutor in the Federal District requested that the Brazilian Justice Department suspend the use of glyphosate.

152. France banned the private sale of Roundup® and glyphosate following the IARC assessment for Glyphosate.

153. Bermuda banned both the private and commercial sale of glyphosates, including Roundup®. The Bermuda government explained its ban as follows: "Following a recent scientific study carried out by a leading cancer agency, the importation of weed spray 'Roundup' has been suspended."

154. The Sri Lankan government banned the private and commercial use of glyphosates, particularly out of concern that glyphosate has been linked to fatal kidney disease in agricultural

workers.

155. The government of Colombia announced its ban on using Roundup® and glyphosate to destroy illegal plantations of coca, the raw ingredient for cocaine, because of the WHO's finding that glyphosate is probably carcinogenic.

DISCOVERY RULE

156. Plaintiffs hereby plead and invoke the "discovery rule" if necessary. Plaintiffs will show that after reasonably exercising due diligence, they did not learn the nature of the cause of their cancer or that such cancer was chemically-related until less than the time periods provided by the relevant statutes of limitations. Plaintiffs also specifically invoke the federally required commencement date as set forth in 42 U.S.C. § 9658.

CLAIMS

COUNT I STRICT LIABILITY (DESIGN DEFECT)

157. Plaintiffs incorporate by reference each and every allegation set forth in the preceding paragraphs as if fully stated herein.

158. Plaintiffs bring this strict liability claim against Monsanto for defective design.

159. At all times relevant to this litigation, Monsanto engaged in the business of testing, developing, manufacturing, selling, distributing, and Monsanto engaged in the marketing, packaging design, and promotion of Roundup® products, which are defective and unreasonably dangerous to consumers, including Plaintiffs, thereby placing Roundup® products into the stream of commerce. These actions were under the ultimate control and supervision of Monsanto. At all times relevant to this litigation, Monsanto designed, researched, developed, manufactured, produced, tested, assembled, labeled, advertised, promoted, marketed, sold, and distributed the Roundup® products used by Plaintiffs, as described above.

160. At all times relevant to this litigation, Roundup® products were manufactured, designed, and labeled in an unsafe, defective, and inherently dangerous manner that was dangerous for use by or exposure to the public, and, in particular, Plaintiffs.

161. At all times relevant to this litigation, Roundup® products reached the intended consumers, handlers, and users or other persons coming into contact with these products in Missouri and throughout the United States, including Plaintiffs, without substantial change in their condition as designed, manufactured, sold, distributed, labeled, and marketed by Monsanto.

162. Roundup® products, as researched, tested, developed, designed, licensed, manufactured, packaged, labeled, distributed, sold, and marketed by Monsanto were defective in design and formulation in that when they left the hands of the manufacturers and/or suppliers, they were unreasonably dangerous and dangerous to an extent beyond that which an ordinary consumer would contemplate.

163. Roundup® products, as researched, tested, developed, designed, licensed, manufactured, packaged, labeled, distributed, sold, and marketed by Monsanto were defective in design and formulation in that when they left the hands of the manufacturers and/or suppliers, the foreseeable risks exceeded the alleged benefits associated with their design and formulation.

164. At all times relevant to this action, Monsanto knew or had reason to know that Roundup® products were defective and were inherently dangerous and unsafe when used in the manner instructed and provided by Monsanto. Therefore, at all times relevant to this litigation, Roundup® products, as researched, tested, developed, designed, licensed, manufactured, packaged, labeled, distributed, sold, and marketed by Monsanto were defective in design and formulation, in one or more of the following ways:

a) When placed in the stream of commerce, Roundup®

products were defective in design and formulation, and, consequently, dangerous to an extent beyond that which an ordinary consumer would contemplate.

- b) When placed in the stream of commerce, Roundup® products were unreasonably dangerous in that they were hazardous and posed a grave risk of cancer and other serious illnesses when used in a reasonably anticipated manner.
- c) When placed in the stream of commerce, Roundup® products contained unreasonably dangerous design defects and were not reasonably safe when used in a reasonably anticipated or intended manner.
- d) Monsanto did not sufficiently test, investigate, or study Roundup® products and, specifically, the active ingredient glyphosate.
- e) Exposure to Roundup® and glyphosate-containing products presents a risk of harmful side effects that outweigh any potential utility stemming from the use of the herbicide.
- f) At the time of marketing its Roundup® products, Roundup® was defective in that exposure to Roundup® and specifically, its active ingredient glyphosate, could result in cancer and other severe illnesses and injuries

and/or death.

- g) Monsanto did not conduct adequate post-marketing surveillance of its Roundup® products.
- h) Monsanto could have employed safer alternative designs and formulations.

165. Plaintiffs were exposed to Roundup® products in the course of their personal and/or work-related use, as described above, without knowledge of their dangerous characteristics.

166. At all times relevant to this litigation, Plaintiffs used and/or were exposed to the use of Roundup® products in an intended or reasonably foreseeable manner without knowledge of their dangerous characteristics.

167. Plaintiffs could not have reasonably discovered the defects and risks associated with Roundup® or glyphosate-containing products before or at the time of exposure.

168. The harm caused by Roundup® products far outweighed their benefit, rendering these products dangerous to an extent beyond that which an ordinary consumer would contemplate. Roundup® products were and are more dangerous than alternative products and Monsanto could have designed Roundup® products (including their packaging and sales aids) to make them less dangerous. Indeed, at the time that Monsanto designed Roundup® products, the state of the industry's scientific knowledge was such that a less risky design or formulation was attainable.

169. At the time Roundup® products left Monsanto's control, there was a practical, technically feasible and safer alternative design that would have prevented the harm without substantially impairing the reasonably anticipated or intended function of those herbicides.

170. Monsanto's defective design of Roundup® products was willful, wanton, fraudulent, malicious, and conducted with reckless disregard for the health and safety of users of

the Roundup® products, including Plaintiffs herein.

171. Therefore, as a result of the unreasonably dangerous condition of its Roundup® products, Monsanto is strictly liable to Plaintiffs.

172. The defects in Roundup® products caused or contributed to cause Plaintiffs' grave injuries and/or death, and, but for Monsanto's misconduct and omissions, Plaintiffs would not have sustained their injuries and/or death.

173. Monsanto's conduct, as described above, was reckless. Monsanto risked the lives of consumers and users of its products, including Plaintiffs, with knowledge of the safety problems associated with Roundup® and glyphosate-containing products, and suppressed this knowledge from the general public. Monsanto made conscious decisions not to redesign, warn, or inform the unsuspecting public. Monsanto's reckless conduct warrants an award of aggravated damages.

174. As a direct and proximate result of Monsanto placing defective Roundup® products into the stream of commerce, Plaintiffs have suffered and continue to suffer grave injuries and/or death, and have endured physical pain and discomfort, as well as economic hardship, including considerable financial expenses for medical care and treatment.

175. WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in Plaintiffs' favor for compensatory and punitive damages in an amount in excess of Twenty-Five Thousand Dollars (\$25,000.00), together with interest, costs herein incurred, and all such other and further relief as this Court deems just and proper. Plaintiffs also demand a jury trial on the issues contained herein.

COUNT II STRICT LIABILITY (FAILURE TO WARN)

176. Plaintiffs incorporate by reference each and every allegation set forth in the

preceding paragraphs as if fully stated herein.

177. Plaintiffs bring this strict liability claim against Monsanto for failure to warn.

178. At all times relevant to this litigation, Monsanto engaged in the business of testing, developing, designing, manufacturing, marketing, selling, distributing, and promoting Roundup® products, which are defective and unreasonably dangerous to consumers, including Plaintiffs, because they do not contain adequate warnings or instructions concerning the dangerous characteristics of Roundup® and, specifically, the active ingredient glyphosate. These actions were under the ultimate control and supervision of Monsanto.

179. Monsanto researched, developed, designed, tested, manufactured, inspected, labeled, distributed, marketed, promoted, sold, and otherwise released into the stream of commerce Roundup® products, and in the course of same, directly advertised or marketed the products to consumers and end users, including Plaintiffs, and therefore had a duty to warn of the risks associated with the use of Roundup® and glyphosate-containing products.

180. At all times relevant to this litigation, Monsanto had a duty to properly test, develop, design, manufacture, inspect, package, label, market, promote, sell, distribute, maintain supply, provide proper warnings, and take such steps as necessary to ensure that Roundup® products did not cause users and consumers to suffer from unreasonable and dangerous risks. Monsanto had a continuing duty to warn Plaintiffs of the dangers associated with Roundup® use and exposure. Monsanto, as manufacturer, seller, promoter, marketer, or distributor of chemical herbicides is held to the knowledge of an expert in the field.

181. At the time of manufacture, Monsanto could have provided the warnings or instructions regarding the full and complete risks of Roundup® and glyphosate-containing products because it knew or should have known of the unreasonable risks of harm associated with

the use of and/or exposure to such products.

182. At all times relevant to this litigation, Monsanto failed to investigate, study, test, or promote the safety or to minimize the dangers to users and consumers of its product and to those who would foreseeably use or be harmed by these herbicides, including Plaintiffs.

183. Despite the fact that Monsanto knew or should have known that Roundup® posed a grave risk of harm, it failed to exercise reasonable care to warn of the dangerous risks associated with use and exposure. The dangerous propensities of these products and the carcinogenic characteristics of glyphosate, as described above, were known to Monsanto, or scientifically knowable to Monsanto through appropriate research and testing by known methods, at the time it distributed, marketed, promoted, supplied, or sold the product, and not known to end users and consumers, such as Plaintiffs.

184. These products created significant risks of serious bodily harm to consumers, as alleged herein, and Monsanto failed to adequately warn consumers and reasonably foreseeable users of the risks of exposure to its products. Monsanto has wrongfully concealed information concerning the dangerous nature of Roundup® and its active ingredient glyphosate, and further made false and/or misleading statements concerning the safety of Roundup® and glyphosate.

185. At all times relevant to this litigation, Roundup® products reached the intended consumers, handlers, and users or other persons coming into contact with these products in Missouri and throughout the United States, including Plaintiffs, without substantial change in their condition as designed, manufactured, sold, distributed, labeled, promoted, and marketed by Monsanto.

186. Plaintiffs were exposed to Roundup® products in the course of their personal and/or work-related use of Roundup®, without knowledge of its dangerous characteristics.

187. At all times relevant to this litigation, Plaintiffs used and/or were exposed to the use of Roundup® products in their intended or reasonably foreseeable manner without knowledge of their dangerous characteristics.

188. Plaintiffs could not have reasonably discovered the defects and risks associated with Roundup® or glyphosate-containing products prior to or at the time of Plaintiffs' exposure. Plaintiffs relied upon the skill, superior knowledge, and judgment of Monsanto.

189. These products were defective because the minimal warnings disseminated with Roundup® products were inadequate, and they failed to communicate adequate information on the dangers and safe use/exposure and failed to communicate warnings and instructions that were appropriate and adequate to render the products safe for their ordinary, intended, and reasonably foreseeable uses, including agricultural and landscaping applications.

190. The information that Monsanto did provide or communicate failed to contain relevant warnings, hazards, and precautions that would have enabled consumers such as Plaintiffs to utilize the products safely and with adequate protection. Instead, Monsanto disseminated information that was inaccurate, false, and misleading and which failed to communicate accurately or adequately the comparative severity, duration, and extent of the risk of injuries and/or death with use of and/or exposure to Roundup® and glyphosate; continued to aggressively promote the efficacy of its products, even after it knew or should have known of the unreasonable risks from use or exposure; and concealed, downplayed, or otherwise suppressed, through aggressive marketing and promotion, any information or research about the risks and dangers of exposure to Roundup® and glyphosate.

190. To this day, Monsanto has failed to adequately and accurately warn of the true risks of Plaintiffs' injuries and/or death associated with the use of and exposure to Roundup® and its

active ingredient glyphosate, a probable carcinogen.

191. As a result of their inadequate warnings, Roundup® products were defective and unreasonably dangerous when they left the possession and/or control of Monsanto, were distributed, marketed, and promoted by Monsanto, and used by Plaintiffs in their personal and/or work-related use.

192. Monsanto is liable to Plaintiffs for injuries and/or death caused by its negligent or willful failure, as described above, to provide adequate warnings or other clinically relevant information and data regarding the appropriate use of these products and the risks associated with the use of or exposure to Roundup® and glyphosate.

193. The defects in Roundup® products caused or contributed to cause Plaintiffs' injuries and/or death, and, but for this misconduct and omissions, Plaintiffs would not have sustained their injuries and/or death. To this day, Monsanto has failed to adequately and accurately warn of the true risks of Plaintiffs' injuries and/or death associated with the use of and exposure to Roundup® and its active ingredient glyphosate, a probable carcinogen.

- a) As a result of their inadequate warnings, Roundup® products were defective and unreasonably dangerous when they left the possession and/or control of Monsanto, were distributed, marketed, and promoted by Monsanto, and used by Plaintiffs in their personal and/or work-related use.
- b) Monsanto is liable to Plaintiffs for injuries and/or death caused by its negligent or willful failure, as described above, to provide adequate warnings or other clinically relevant information and data regarding the appropriate use

of these products and the risks associated with the use of or exposure to Roundup® and glyphosate.

- c) The defects in Roundup® products caused or contributed to cause Plaintiffs' injuries and/or death, and, but for this misconduct and omissions, Plaintiffs would not have sustained their injuries and/or death.
- d) Had Monsanto provided adequate warnings and instructions and properly disclosed and disseminated the risks associated with Roundup® products, Plaintiffs could have avoided the risk of developing injuries and/or death as alleged herein.
- e) As a direct and proximate result of Monsanto placing defective Roundup® products into the stream of commerce, Plaintiffs have suffered severe injuries and/or death and have endured physical pain and discomfort, as well as economic hardship, including considerable financial expenses for medical care and treatment.

195. WHEREFORE, Plaintiffs respectfully requests that this Court enter judgment in Plaintiffs' favor for compensatory and punitive damages in an amount in excess of Twenty-Five Thousand Dollars (\$25,000.00) together with interest, costs herein incurred, and all such other and further relief as this Court deems just and proper. Plaintiffs also demand a jury trial on the issues contained herein.

COUNT III NEGLIGENCE

196. Plaintiffs incorporate by reference each and every allegation set forth in the preceding paragraphs as if fully stated herein.

197. Monsanto, directly or indirectly, caused Roundup® products to be sold, distributed, packaged, labeled, marketed, promoted, and/or used by Plaintiffs.

198. At all times relevant to this litigation, Monsanto had a duty to exercise reasonable care in the design, research, manufacture, marketing, advertisement, supply, promotion, packaging, sale, and distribution of Roundup® products, including the duty to take all reasonable steps necessary to manufacture, promote, and/or sell a product that was not unreasonably dangerous to consumers and users of the product.

199. At all times relevant to this litigation, Monsanto had a duty to exercise reasonable care in the marketing, advertisement, and sale of the Roundup® products. Monsanto's duty of care owed to consumers and the general public included providing accurate, true, and correct information concerning the risks of using Roundup® and appropriate, complete, and accurate warnings concerning the potential adverse effects of exposure to Roundup®, and, in particular, its active ingredient glyphosate.

200. At all times relevant to this litigation, Monsanto knew or, in the exercise of reasonable care, should have known of the hazards and dangers of Roundup® and specifically, the carcinogenic properties of the chemical glyphosate.

201. Accordingly, at all times relevant to this litigation, Monsanto knew or, in the exercise of reasonable care, should have known that use of or exposure to its Roundup® products could cause or be associated with Plaintiffs' injuries and/or death and thus created a dangerous and unreasonable risk of injury to the users of these products, including Plaintiffs.

202. Monsanto also knew or, in the exercise of reasonable care, should have known that users and consumers of Roundup® were unaware of the risks and the magnitude of the risks associated with use of and/or exposure to Roundup® and glyphosate-containing products.

203. As such, Monsanto breached the duty of reasonable care and failed to exercise ordinary care in the design, research, development, manufacture, testing, marketing, supply, promotion, advertisement, packaging, sale, and distribution of its Roundup® products, in that Monsanto manufactured, marketed, promoted, and sold defective herbicides containing the chemical glyphosate, knew or had reason to know of the defects inherent in these products, knew or had reason to know that a user's or consumer's exposure to the products created a significant risk of harm and unreasonably dangerous side effects, and failed to prevent or adequately warn of these risks and injuries and/or death.

204. Despite an ability and means to investigate, study, and test these products and to provide adequate warnings, Monsanto has failed to do so. Indeed, Monsanto has wrongfully concealed information and has further made false and/or misleading statements concerning the safety and/or exposure to Roundup® and glyphosate.

205. Monsanto was negligent in the following respects:

- a) Manufacturing, producing, promoting, formulating, creating, developing, designing, selling, and/or distributing its Roundup® products without thorough and adequate pre- and post-market testing;
- b) Manufacturing, producing, promoting, formulating, creating, developing, designing, selling, and/or distributing Roundup® while negligently and/or intentionally concealing and failing to

disclose the results of trials, tests, and studies of exposure to glyphosate, and, consequently, the risk of serious harm associated with human use of and exposure to Roundup®;

- c) Failing to undertake sufficient studies and conduct necessary tests to determine whether or not Roundup® products and glyphosatecontaining products were safe for their intended use in agriculture and horticulture;
- d) Failing to use reasonable and prudent care in the design, research, manufacture, and development of Roundup® products so as to avoid the risk of serious harm associated with the prevalent use of Roundup®/glyphosate as an herbicide;
- e) Failing to design and manufacture Roundup® products so as to ensure they were at least as safe and effective as other herbicides on the market;
- f) Failing to provide adequate instructions, guidelines, and safety precautions to those persons who Monsanto could reasonably foresee would use and be exposed to its Roundup® products;
- g) Failing to disclose to Plaintiffs, users/consumers, and the general public that use of and exposure to Roundup® presented severe risks of cancer and other grave illnesses;
- h) Failing to warn Plaintiffs, users/consumers, and the general public that the product's risk of harm was unreasonable and that there were safer and effective alternative herbicides available to

Plaintiffs and other consumers;

- i) Systematically suppressing or downplaying contrary evidence about the risks, incidence, and prevalence of the side effects of Roundup® and glyphosate-containing products;
- j) Representing that its Roundup® products were safe for their intended use when, in fact, Monsanto knew or should have known that the products were not safe for their intended purpose;
- k) Declining to make or propose any changes to Roundup® products' labeling or other promotional materials that would alert the consumers and the general public of the risks of Roundup® and glyphosate;
- Advertising, marketing, and recommending the use of the Roundup® products, while concealing and failing to disclose or warn of the dangers known by Monsanto to be associated with or caused by the use of or exposure to Roundup® and glyphosate;
- m) Continuing to disseminate information to its consumers, which indicate or imply that Monsanto's Roundup® products are not unsafe for use in the agricultural and horticultural industries; and
- n) Continuing the manufacture and sale of its products with the knowledge that the products were unreasonably unsafe and dangerous.

206. Monsanto knew and/or should have known that it was foreseeable that consumers such as Plaintiffs would suffer injuries and/or death as a result of Monsanto's failure to exercise

ordinary care in the manufacturing, marketing, promotion, labeling, distribution, and sale of Roundup®.

207. Plaintiffs did not know the nature and extent of the injuries and/or death that could result from the intended use of and/or exposure to Roundup® or its active ingredient glyphosate.

208. Monsanto's negligence was the proximate cause of the injuries and/or death, harm, and economic losses that Plaintiffs suffered, as described herein.

209. Monsanto's conduct, as described above, was reckless. Monsanto regularly risked the lives of consumers and users of its products, including Plaintiffs, with full knowledge of the dangers of these products. Monsanto has made conscious decisions not to redesign, re-label, warn, or inform the unsuspecting public, including Plaintiffs. Monsanto's reckless conduct therefore warrants an award of aggravated or punitive damages.

210. As a proximate result of Monsanto's wrongful acts and omissions in placing defective Roundup® products into the stream of commerce without adequate warnings of the hazardous and carcinogenic nature of glyphosate, Plaintiffs have suffered severe and permanent physical and emotional injuries. Plaintiffs have endured pain and suffering and has suffered economic losses (including significant expenses for medical care and treatment) in an amount to be determined.

211. WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in Plaintiffs' favor for compensatory and punitive damages in an amount in excess of Twenty-Five Thousand Dollars (\$25,000.00) together with interest, costs herein incurred, and all such other and further relief as this Court deems just and proper. Plaintiffs also demand a jury trial on the issues contained herein.

COUNT IV

FRAUD, MISREPRESENTATION, AND SUPPRESSION

206. Plaintiffs incorporate by reference each and every allegation set forth in the preceding paragraphs as if fully stated herein.

212. Defendant fraudulently, intentionally, and/or negligently misrepresented to the public, and to the Plaintiffs, both directly and by and through the media, the scientific literature and purported "community outreach" programs, the safety of Roundup products, and/or fraudulently, intentionally, and/or negligently concealed, suppressed, or omitted material, adverse information regarding the safety of Roundup.

213. The intentional and/or negligent misrepresentations and omissions of Defendant regarding the safety of Roundup products were communicated to Plaintiffs directly through ghostwritten articles, editorials, national and regional advertising, marketing and promotion efforts, as well as the packaging and sales aids. The safety of Roundup products was also intentionally and/or negligently misrepresented to Plaintiffs and the public with the intent that such misrepresentations would cause Plaintiffs and other potential consumers to purchase and use or continue to purchase and use Roundup products.

214. Defendant either knew or should have known of the material representations they were making regarding the safety and relative utility of Roundup products.

215. Defendant fraudulently, intentionally, and/or negligently made the misrepresentations and/or actively concealed, suppressed, or omitted this material information with the specific desire to induce Plaintiffs, and the consuming public to purchase and use Roundup products. Defendant fraudulently, intentionally, and/or negligently, knew or should have known that Plaintiffs and the consuming public would rely on such material

misrepresentations and/or omissions in selecting and applying Roundup products. Defendant knew or should have known that Plaintiffs would rely on their false representations and omissions.

217. Defendant made these misrepresentations and actively concealed adverse information including the risk of non-Hodgkin's lymphoma, at a time when, their agents and/or employees knew or should have known, the product had defects, dangers, and characteristics that were other than what was represented to the consuming public.

218. Despite the fact that Defendant knew or should have known of reports of severe risks including non-Hodgkin's lymphoma, with Roundup use and exposure, this information was strategically minimized, understated, or omitted in order to create the impression that the human dangers of Roundup were nonexistent, particularly in light of its purported utility.

219. The fraudulent, intentional and/or negligent material misrepresentations and/or active concealment, suppression, and omissions by Defendant were perpetuated directly and/or indirectly through the advertisements, packaging, sales aids, furtive public relations efforts, and other marketing and promotional pieces.

220. If Plaintiffs had known the true facts concerning the risks associated with Roundup exposure, Plaintiffs would have used a safer alternative.

221. Plaintiffs reliance upon the material misrepresentations and omissions was justified, among other reasons, because said misrepresentations and omissions were made by individuals and entities who were in a position to know the true facts concerning Roundup while Plaintiffs were not in a position to know the true facts because Defendant overstated the benefits and safety of Roundup and downplayed the risk of non-Hodgkin's lymphoma, thereby inducing Plaintiffs to use the herbicide rather than safer alternatives.

222. As a direct and proximate result of Defendant' actions and inactions, Plaintiffs were exposed to Roundup and suffered and will continue to suffer injuries and damages, as set forth herein.

223. WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in Plaintiffs' favor for compensatory and punitive damages in an amount in excess of Twenty-Five Thousand Dollars (\$25,000.00) together with interest, costs herein incurred, and all such other and further relief as this Court deems just and proper. Plaintiffs also demand a jury trial on the issues contained herein.

COUNT V

VIOLATION OF THE CONSUMER FRAUD ACTS

224. Plaintiffs incorporate by reference each and every allegation set forth in the preceding paragraphs as if fully stated herein., which allege fraud with specificity.

225. Defendant fraudulently, intentionally, negligently, and/or innocently misrepresented to the public, and to the Plaintiffs, both directly and by and through the media and purported "community outreach" programs, the safety of Roundup products, and/or fraudulently, intentionally, negligently and/or innocently concealed, suppressed, or omitted material, adverse information regarding the safety of Roundup. This deception caused injury to Plaintiff in violation of the Consumer Fraud Act of the Plaintiffs' home states which create private rights of action by the Plaintiffs.

226. The intentional, negligent, and/or innocent misrepresentations and omissions of Defendant regarding the safety of Roundup products were communicated to Plaintiffs directly through national and regional advertising, marketing and promotion efforts, as well as the packaging and sales aids. The safety of Roundup products was also intentionally, negligently,

and/or innocently misrepresented to Plaintiffs and the public with the intent that such misrepresentations would cause Plaintiffs and other potential consumers to purchase and use or continue to purchase and use Roundup products.

227. Defendant either knew or should have known of the material representations they were making regarding the safety and relative utility of Roundup products.

228. Defendant fraudulently, intentionally, negligently, and/or innocently made the misrepresentations and/or actively concealed, suppressed, or omitted this material information with the specific desire to induce Plaintiffs, and the consuming public to purchase and use Roundup products. Defendant f fraudulently, intentionally, negligently, and/or innocently, knew or should have known that Plaintiffs and the consuming public would rely on such material misrepresentations and/or omissions in selecting and applying Roundup products. Defendant knew or should have known that Plaintiffs would rely on their false representations and omissions.

229. Defendant made these misrepresentations and actively concealed adverse information including the risk of non-Hodgkin's lymphoma, at a time when, their agents and/or employees knew or should have known, the product had defects, dangers, and characteristics that were other than what was represented to the consuming public. Specifically, Defendant misrepresented and actively concealed, suppressed, and omitted that there had been inadequate testing of the safety and efficacy of Roundup, and that prior studies, research, reports, and/or testing had been conducted linking the use of the drug with serious health events, including non-Hodgkin's lymphoma.

230. Despite the fact that Defendant knew or should have known of reports of severe risks including non-Hodgkin's lymphoma, with Roundup use and exposure, this information was

strategically minimized, understated, or omitted in order to create the impression that the human dangers of Roundup were nonexistent, particularly in light of its purported utility.

231. The fraudulent, intentional, negligent and/or innocent material misrepresentations and/or active concealment, suppression, and omissions by Defendant were perpetuated directly and/or indirectly through the advertisements, packaging, sales aids, furtive public relations efforts, and other marketing and promotional pieces authored, analyzed, created, compiled, designed, drafted, disseminated, distributed, edited, evaluated, marketed, published, and supplied by Defendant.

232. If Plaintiffs had known the true facts concerning the risks associated with Roundup exposure, Plaintiffs would have used a safer alternative.

233. Plaintiffs' reliance upon the material misrepresentations and omissions was justified, among other reasons, because said misrepresentations and omissions were made by individuals and entities who were in a position to know the true facts concerning Roundup while Plaintiffs were not in a position to know the true facts because Defendant overstated the benefits and safety of Roundup and downplayed the risk of non-Hodgkin's lymphoma, thereby inducing Plaintiffs to use the herbicide rather than safer alternatives.

234. Federal law and the EPA do not authorize and specifically prohibit the deceptions, misrepresentations and omissions made by Defendant.

235. As a direct and proximate result of Defendant' actions and inactions, Plaintiffs were exposed to Roundup and suffered, and will continue to suffer, injuries and damages, as set forth herein.

236. WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in Plaintiffs' favor for compensatory and punitive damages in an amount in excess of Twenty-Five

Thousand Dollars (\$25,000.00) together with interest, costs herein incurred, and all such other and further relief as this Court deems just and proper. Plaintiffs also demand a jury trial on the issues contained herein.

JURY DEMAND

237. PLAINTIFFS DEMAND A TRIAL BY JURY ON ALL COUNTS.

Dated: August 14, 2019

CAREY DANIS & LOWE

By: <u>/s/ Sarah Shoemake Doles</u> Jeffrey J. Lowe, #35114 John F. Garvey, #35879 Sarah Shoemake Doles, #45747 Alyson M. Petrick, #68323 8235 Forsyth Boulevard, Suite 1100 St. Louis, MO 63105 Telephone: (314) 725-7700 Facsimile: (314) 725-7700 Facsimile: (314) 721-0905 jlowe@careydanis.com jgarvey@careydanis.com sdoles@careydanis.com apetrick@careydanis.com

Matthew R. McCarley* Texas Bar No. 24041426 mccarley@fnlawfirm.com **FEARS | NACHAWATI, PLLC** 5473 Blair Road Dallas, TX 75231 Tel. (214) 890-0711 Fax (214) 890-0712

Jonathan P. Novak* Maryland Bar No. 20282 jnovak@fnlawfirm.com FEARS | NACHAWATI, PLLC 5473 Blair Road Dallas, TX 75231 Tel. (214) 890-0711 Fax (214) 890-0712

*To be admitted pro hac vice

Attorneys for Plaintiffs